<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://ijhse.com/lib/pkp/xml/oai2.xsl" ?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/
		http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
	<responseDate>2026-03-13T20:37:40Z</responseDate>
	<request verb="ListRecords" metadataPrefix="oai_dc">https://ijhse.com/index.php/files/oai</request>
	<ListRecords>
		<record>
			<header>
				<identifier>oai:ojs.ijhse.com:article/1</identifier>
				<datestamp>2025-12-15T08:43:04Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Mesalamine Microemulsions for Crohn’s Disease: A Review</dc:title>
	<dc:creator xml:lang="en">Subham Mandal</dc:creator>
	<dc:creator xml:lang="en">Suraj Mandal</dc:creator>
	<dc:subject xml:lang="en">Crohn&#039;s Disease, Mesalamine, Microemulsions, Bioavailability, Targeted Drug Delivery, pH-sensitive Systems, Controlled Release</dc:subject>
	<dc:description xml:lang="en">This analysis delves into the promise of mesalamineencapsulated microemulsions in improving bioavailability and therapeutic effectiveness for Crohn&#039;s disease. Crohn’s disease, a persistent inflammatory condition of the bowel, frequently necessitates precise medication administration owing to the particular sites of inflammation found in the gastrointestinal system. Mesalamine, a commonly utilised treatment, exhibits restricted efficacy owing to its inadequate absorption in the upper gastrointestinal tract and swift metabolic breakdown. This manuscript explores the obstacles linked to conventional mesalamine formulations and investigates the latest innovations in microemulsion-driven delivery mechanisms aimed at enhancing drug solubility, stability, and precise targeting. Innovative microemulsion methodologies, such as pH-sensitive and enzymeresponsive frameworks, exhibit potential in overcoming the shortcomings of current therapies, creating opportunities for more efficient and patient-centric treatment alternatives.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2025-02-17</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijhse.com/index.php/files/article/view/1</dc:identifier>
	<dc:identifier>10.62896/ijhse.v1.i1.01</dc:identifier>
	<dc:source xml:lang="en">International Journal of Health Sciences and Engineering; IJHSE: Volume 1 , Issue 1, Jan-June, 2025; 1-8</dc:source>
	<dc:source>3049-3811</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijhse.com/index.php/files/article/view/1/1</dc:relation>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijhse.com:article/2</identifier>
				<datestamp>2025-12-15T08:43:04Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Deciphering Anxiety with Zebrafish: A Versatile Model for Anxiolytic Studies</dc:title>
	<dc:creator xml:lang="en">Neeru Singh</dc:creator>
	<dc:creator xml:lang="en">Lakhan Singh</dc:creator>
	<dc:creator xml:lang="en">Kulsoom Hamid</dc:creator>
	<dc:creator xml:lang="en">Vikrant Singh</dc:creator>
	<dc:subject xml:lang="en">–zebrafish, anxiety, shoal cohesion</dc:subject>
	<dc:description xml:lang="en">Background - Studies on behavioral pharmacology are increasingly using zebrafish as model organisms. Numerous anxiety-related behaviors in zebrafish have been documented, yet little is known about how anxiolytic drugs impact these behaviors. Anxiety is currently one of the primary unmet medical needs. Despite the wide variety of anxiolytic drugs available, many patients either do not respond well to current pharmacotherapy or see a lessening of their reactivity with repeated treatment. Search for novel compounds and learn how anxiolytic drugs function. Main body of the abstract - In the first task, we concurrently looked at the adult zebrafish&#039;s motility, color, height in the tank, and cohesiveness of the shoal. We examine the effects of buspirone hydrochloride, ethanol, benzodiazepines, and a common anxiolytic drug used in medical facilities for humans. Anxiolysis&#039;s symptoms were not brought on by anxiolytic drugs, which work by agonisting GABA receptors. We search for anxiolytic drugs in two genetically distinct populations of zebrafish, and the results show that the light/dark preference test is a sensitive, practical, and cost-effective technique. Two important behavioral characteristics seem to be shoal cohesion and tank height among the various groups of these treatments. Conclusion - The findings show that measuring the effects of human anxiolytic medications may be done simply and sensitively using zebrafish behavior.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2025-02-17</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijhse.com/index.php/files/article/view/2</dc:identifier>
	<dc:identifier>10.62896/v1.i1.02</dc:identifier>
	<dc:source xml:lang="en">International Journal of Health Sciences and Engineering; IJHSE: Volume 1 , Issue 1, Jan-June, 2025; 9-15</dc:source>
	<dc:source>3049-3811</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijhse.com/index.php/files/article/view/2/2</dc:relation>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijhse.com:article/3</identifier>
				<datestamp>2025-12-15T08:43:03Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Enhanced Bioavailability and Targeted Delivery of Mesalamine for Crohn’s Disease Using Microemulsion Formulations</dc:title>
	<dc:creator xml:lang="en">Km. Bhumika</dc:creator>
	<dc:creator xml:lang="en">Shadab Ali</dc:creator>
	<dc:creator xml:lang="en">Iram Jahan</dc:creator>
	<dc:creator xml:lang="en">Mukesh Kumar</dc:creator>
	<dc:creator xml:lang="en">Subham Mandal</dc:creator>
	<dc:creator xml:lang="en">Suraj Mandal</dc:creator>
	<dc:subject xml:lang="en">Crohn&#039;s disease, Mesalamine bioavailability, Microemulsion formulations, GI tract targeting¸ Drug encapsulation efficiency</dc:subject>
	<dc:description xml:lang="en">This study evaluates mesalamine-loaded microemulsions designed to enhance drug bioavailability and site-specific delivery in the gastrointestinal (GI) tract, targeting the treatment of Crohn&#039;s disease. Mesalamine, an anti-inflammatory drug, is conventionally limited by poor solubility and inconsistent site-specific action. This research examines various microemulsion formulations to improve mesalamine delivery to the colon, assessing parameters such as stability, droplet size, encapsulation efficiency, and pH-controlled release. Optimal formulations demonstrated controlled, targeted release in colonic conditions, high stability, and minimized premature drug release in nontarget GI regions. These findings suggest potential clinical applications for advanced mesalamine therapies in Crohn&#039;s disease management.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2025-02-17</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijhse.com/index.php/files/article/view/3</dc:identifier>
	<dc:identifier>10.62896/v1.i1.03</dc:identifier>
	<dc:source xml:lang="en">International Journal of Health Sciences and Engineering; IJHSE: Volume 1 , Issue 1, Jan-June, 2025; 16-20</dc:source>
	<dc:source>3049-3811</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijhse.com/index.php/files/article/view/3/3</dc:relation>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijhse.com:article/4</identifier>
				<datestamp>2025-12-15T08:43:03Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Impact of Electronic Health Records and Automation on Pharmaceutical Management Efficiency: A Narrative Review</dc:title>
	<dc:creator xml:lang="en">Subham Mandal</dc:creator>
	<dc:creator xml:lang="en">Mukesh Kumar</dc:creator>
	<dc:creator xml:lang="en">Km. Bhumika</dc:creator>
	<dc:creator xml:lang="en">Shadab Ali</dc:creator>
	<dc:creator xml:lang="en">Iram Jahan</dc:creator>
	<dc:creator xml:lang="en">Suraj Mandal</dc:creator>
	<dc:subject xml:lang="en">Electronic Health Records, Automation, Pharmaceutical Management, Artificial Intelligence, Medication Safety, Interoperability</dc:subject>
	<dc:description xml:lang="en">The integration of Electronic Health Records (EHRs) and automation in pharmaceutical management has significantly improved medication safety, inventory control, and workflow efficiency. EHRs facilitate realtime access to patient data, enabling healthcare providers to make informed decisions while reducing prescription errors and ensuring adherence to treatment protocols. Automation technologies, including computerized physician order entry (CPOE), robotic dispensing systems, and artificial intelligence (AI)-driven inventory management, have optimized pharmaceutical supply chains, minimized wastage, and enhanced medication dispensing accuracy. However, challenges such as interoperability issues, cybersecurity threats, high implementation costs, and resistance to technological adoption hinder the full potential of these advancements. Addressing these challenges requires the development of standardized data-sharing protocols, regulatory frameworks for AIdriven decision-making, and enhanced cybersecurity measures. Future advancements in AI, blockchain technology, and predictive analytics hold promise for further improving pharmaceutical management. This review explores the impact of EHRs and automation on pharmaceutical efficiency, highlighting both the benefits and limitations of these technologies while discussing strategies for their effective implementation in modern healthcare systems.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2025-02-17</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijhse.com/index.php/files/article/view/4</dc:identifier>
	<dc:identifier>10.62896/v1.i1.04</dc:identifier>
	<dc:source xml:lang="en">International Journal of Health Sciences and Engineering; IJHSE: Volume 1 , Issue 1, Jan-June, 2025; 21-36</dc:source>
	<dc:source>3049-3811</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijhse.com/index.php/files/article/view/4/4</dc:relation>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijhse.com:article/5</identifier>
				<datestamp>2025-12-15T08:43:03Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Targeted Drug Delivery Systems in Oncology: A Review of Recent Patents and future directions</dc:title>
	<dc:creator xml:lang="en">Mukesh Kumar</dc:creator>
	<dc:creator xml:lang="en">Subham Manda</dc:creator>
	<dc:creator xml:lang="en">Km. Bhumika</dc:creator>
	<dc:creator xml:lang="en">Shadab Ali</dc:creator>
	<dc:creator xml:lang="en">Iram Jahan</dc:creator>
	<dc:creator xml:lang="en">Suraj Mandal</dc:creator>
	<dc:subject xml:lang="en">Targeted Drug Delivery, Oncology, Nanotechnology, Immunotherapy, Antibody-Drug Conjugates</dc:subject>
	<dc:description xml:lang="en">Cancer remains a global health challenge, necessitating innovative treatment strategies to improve outcomes while minimizing side effects. Targeted Drug Delivery Systems (TDDS) have revolutionized oncology by addressing limitations of traditional chemotherapy, such as systemic toxicity, lack of specificity, and drug resistance. Utilizing nanotechnology, biomarker-based targeting, and immunotherapy, TDDS enables precise drug delivery to tumors, enhancing efficacy while protecting healthy tissues. Nanotechnology has facilitated the development of liposomes, dendrimers, micelles, and solid lipid nanoparticles, leveraging the Enhanced Permeability and Retention (EPR) effect for tumor accumulation. Examples like Doxil, a PEGylated liposomal doxorubicin, have improved ovarian cancer treatment by reducing cardiotoxicity. Biomarker-based approaches, such as antibody-drug conjugates (ADCs), further enhance specificity. Trastuzumab emtansine (Kadcyla), targeting HER2-positive breast cancer, has demonstrated improved survival rates. TDDS also integrates with immunotherapy to boost immune checkpoint inhibitors, enhance antigen delivery, and optimize cytokine therapy. Lipid nanoparticles and dendrimers are being engineered to improve immune responses while minimizing adverse effects. However, challenges such as tumor heterogeneity, drug resistance, high production costs, and regulatory barriers limit widespread adoption. Ongoing research focuses on overcoming these barriers through personalized medicine, AI-driven designs, and sustainable platforms. TDDS represents a paradigm shift in oncology, combining precision and safety to improve patient outcomes. By integrating emerging technologies and addressing current limitations, TDDS holds the potential to transform cancer treatment, offering hope for better survival and quality of life.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2025-02-17</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijhse.com/index.php/files/article/view/5</dc:identifier>
	<dc:identifier>10.62896/v1.i1.05</dc:identifier>
	<dc:source xml:lang="en">International Journal of Health Sciences and Engineering; IJHSE: Volume 1 , Issue 1, Jan-June, 2025; 37-57</dc:source>
	<dc:source>3049-3811</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijhse.com/index.php/files/article/view/5/5</dc:relation>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijhse.com:article/8</identifier>
				<datestamp>2025-12-15T08:43:03Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Empowering Data Engineering Pipelines with Zero-Shot Learning for Seamless Automated Mapping</dc:title>
	<dc:creator xml:lang="en">Yuvaraj Kavala</dc:creator>
	<dc:subject xml:lang="en">Zero-Shot Learning, Data Engineering, Automated Data Mapping, Semantic Embeddings, Schema Matching, Ontology Alignment, Data Integration, Unsupervised Learning</dc:subject>
	<dc:description xml:lang="en">Zero-shot learning (ZSL), which enables models to recognize unseen classes without prior labeled examples, has gained significant interest in machine learning, yet its application in data engineering—particularly for automating data mapping across heterogeneous sources—remains underexplored. Data mapping, the alignment of data attributes between disparate systems, is traditionally labour-intensive and error-prone, limiting scalability in complex integration scenarios. This paper proposes a novel zero-shot learning framework designed to fully automate data mapping without the need for extensive labeled data. Leveraging semantic embeddings, natural language processing, and ontology alignment, the approach infers attribute mappings by understanding semantic relationships and domain context in an unsupervised manner. Evaluations on real-world healthcare and financial datasets featuring diverse and evolving schemas demonstrate that the framework achieves over 90% mapping accuracy on unseen attribute pairs, outperforming baseline unsupervised and rule-based methods. Precision and recall metrics further confirm its robustness across heterogeneous data types. Qualitative feedback from domain experts highlights the high interpretability and practical usefulness of automated mapping explanations, fostering greater trust and easier downstream validation. Compared to traditional supervised approaches, the zero-shot framework significantly reduces dependence on labeled data and manual effort, accelerating deployment timelines by up to 40%. Case studies also showcase its ability to adapt seamlessly to schema changes without retraining, emphasizing scalability and flexibility in dynamic data environments. While semantic ambiguities occasionally impact mapping precision, future work will focus on improved disambiguation mechanisms. Overall, this study demonstrates the potential of integrating zero-shot learning into data engineering pipelines to transform data integration workflows and support intelligent, adaptable data ecosystems.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2025-02-17</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijhse.com/index.php/files/article/view/8</dc:identifier>
	<dc:identifier>10.62896/v1.i1.06</dc:identifier>
	<dc:source xml:lang="en">International Journal of Health Sciences and Engineering; IJHSE: Volume 1 , Issue 1, Jan-June, 2025; 58-67</dc:source>
	<dc:source>3049-3811</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijhse.com/index.php/files/article/view/8/6</dc:relation>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijhse.com:article/10</identifier>
				<datestamp>2025-12-16T10:40:06Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Generative Healing: AI-Driven Reconstruction of Damaged Medical Images for Low-Infrastructure Healthcare</dc:title>
	<dc:creator xml:lang="en">Shylaja Chityala</dc:creator>
	<dc:subject xml:lang="en">Generative AI, Medical Image Reconstruction, CT/MRI Restoration, Resource-Limited Hospitals, GAN, VAE, Image Inpainting, Deep Learning in Healthcare</dc:subject>
	<dc:description xml:lang="en">Medical imaging plays a pivotal role in clinical diagnostics, yet in many resource-limited hospitals and rural healthcare centers, the acquisition and preservation of high-quality CT and MRI scans are often compromised due to hardware degradation, motion artifacts, transmission noise, and incomplete data capture. These issues severely impact diagnostic accuracy and limit timely medical intervention. In response, this paper presents a robust Generative AI-based reconstruction framework that virtually restores degraded or partially corrupted medical images without requiring additional scans or expensive infrastructure upgrades. The proposed system integrates a Variational Autoencoder (VAE) to model global anatomical priors, a Generative Adversarial Network (GAN) for generating visually realistic textures, and an attention mechanism that adaptively prioritizes damaged regions during reconstruction. Trained on annotated CT and MRI datasets from public repositories such as BraTS and TCIA, the model optimizes a hybrid loss function combining pixelwise, adversarial, and perceptual components to balance accuracy and realism. Extensive quantitative evaluations demonstrate the superiority of the proposed method over traditional models. It achieves a Peak Signal-toNoise Ratio (PSNR) of 31.2 dB, Structural Similarity Index (SSIM) of 0.91, Fréchet Inception Distance (FID) of 32.6, and an average Radiologist Grading Score (RGS) of 4.6 out of 5. Furthermore, the model is successfully deployed on a Raspberry Pi 4B, achieving 2.1 frames per second (FPS) inference, validating its real-time applicability in low-power settings. This framework offers a scalable, cost-effective solution to bridge the diagnostic imaging gap in under-resourced healthcare environments.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2025-12-16</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijhse.com/index.php/files/article/view/10</dc:identifier>
	<dc:identifier>10.62896/ijhse.v1.i2.01</dc:identifier>
	<dc:source xml:lang="en">International Journal of Health Sciences and Engineering; IJHSE: Volume 1 , Issue 2, July-Dec, 2025; 1-9</dc:source>
	<dc:source>3049-3811</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijhse.com/index.php/files/article/view/10/7</dc:relation>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijhse.com:article/11</identifier>
				<datestamp>2025-12-16T10:40:06Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Integration of Evidence-Based Practice in Nursing Science</dc:title>
	<dc:creator xml:lang="en">Oudah Abdullah Alanazi</dc:creator>
	<dc:creator xml:lang="en">Nasser Sanad Alotaibi</dc:creator>
	<dc:creator xml:lang="en">Ghudayan Manzil Alanazi</dc:creator>
	<dc:creator xml:lang="en">Reham Saleh Alsuwih</dc:creator>
	<dc:creator xml:lang="en">Naïf Hussain Farhan Alanazi</dc:creator>
	<dc:subject xml:lang="en">Evidence-Based Practice, Nursing, Implementation strategies, Clinical decision support, Leadership, Education, Patient outcomes.</dc:subject>
	<dc:description xml:lang="en">Background: Evidence-Based Practice (EBP) is essential in modern nursing for improving patient outcomes, enhancing quality of care, and ensuring safety. Despite its proven benefits, adoption remains inconsistent across healthcare settings due to barriers such as lack of training, limited resources, and resistance to change. Understanding these challenges and identifying effective strategies are critical for integrating EBP into routine nursing practice. Methodology: This review synthesizes findings from scientific literature, policy documents, and clinical implementation studies. It evaluates educational interventions, organizational frameworks, and technological tools that support EBP adoption. Key strategies assessed include leadership support, mentorship programs, continuing professional development, and digital platforms facilitating access to clinical guidelines and research evidence. Results: Evidence shows that structured training programs, interdisciplinary collaboration, and leadership engagement significantly increase nurses’ confidence and use of EBP. Digital innovations such as online evidence repositories, AI-driven clinical decision support tools, and mobile health applications further strengthen implementation. However, persistent barriers include time constraints, inadequate staffing, limited funding, and organizational cultures resistant to change. Conclusion: Integrating EBP into nursing requires a multipronged approach that combines leadership commitment, staff empowerment, continuous education, and supportive technologies. Sustainable adoption depends on aligning institutional policies with evidence-based standards and fostering a culture that values inquiry and innovation. Future directions include embedding AI-driven decision tools, strengthening mentorship models, and expanding international collaborations to create a resilient and globally unified evidence-based nursing workforce.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2025-12-16</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijhse.com/index.php/files/article/view/11</dc:identifier>
	<dc:identifier>10.62896/ijhse.v1.i2.02</dc:identifier>
	<dc:source xml:lang="en">International Journal of Health Sciences and Engineering; IJHSE: Volume 1 , Issue 2, July-Dec, 2025; 10-21</dc:source>
	<dc:source>3049-3811</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijhse.com/index.php/files/article/view/11/8</dc:relation>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijhse.com:article/12</identifier>
				<datestamp>2025-12-16T10:40:06Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Recent Advances in Nanotechnology for Drug Delivery</dc:title>
	<dc:creator xml:lang="en">Mohanad Ahmad Alghamdi</dc:creator>
	<dc:creator xml:lang="en">Abdullah Mohammadali Iskandarani</dc:creator>
	<dc:creator xml:lang="en">Ahmed Saeed Ibrahim Alzahrani</dc:creator>
	<dc:subject xml:lang="en">Nanotechnology, Drug Delivery, Nanocarriers, Cancer Nanomedicine, Stimuli-Responsive Release, Controlled Release.</dc:subject>
	<dc:description xml:lang="en">Background: For many years, the mainstay of therapeutic intervention has been traditional drug delivery methods, such as tablets, capsules, injections, and topical formulations. Nevertheless, these methods have significant limitations that ultimately restrict clinical results and patient safety, including inadequate bioavailability, systemic toxicity, lack of regulated release, and poor selectivity. The development of nanotechnology has made it possible to precisely and logically build nanoscale carriers, opening up revolutionary avenues for medication delivery. These nanocarriers—ranging from liposomes and polymeric nanoparticles to dendrimers, inorganic platforms, and biomimetic systems—offer unprecedented control over pharmacokinetics, target-site accumulation, and multifaceted therapy. Methodology: This analytical review collates evidence from recent scientific literature—including PubMed, clinical trials, regulatory agency reports, and mainstream research platforms. A systematic approach is used to summarize the evolution of nanocarrier designs, mechanism of action (passive/active targeting, stimuli-responsive release, controlled/sustained delivery), and the diverse applications in cancer therapy, infectious disease management, gene delivery (siRNA, CRISPR), barrier-crossing strategies (e.g., blood–brain barrier), and personalized medicine. The review also critically evaluates recent innovations—such as smart, multifunctional and biodegradable nanocarriers, nanorobots, hybrid theranostic platforms, green synthesis, and clinically translated FDA-approved products—while outlining future opportunities including integration with artificial intelligence, patient-specific profiling, and regenerative medicine. Results: Nanotechnology-based drug delivery systems have successfully demonstrated improved bioavailability, reduced systemic toxicity, targeted and responsive drug release, and the ability to cross biological barriers. Major clinical milestones comprise FDA approval of nanomedicines (e.g., Doxil®, Abraxane®), the use of lipid nanoparticles in mRNA COVID-19 vaccines, and promising results in gene and immunotherapies. Smart nanocarriers now allow on-demand, sustained, and sitespecific drug release. The rapid integration of AI and machine learning into nanomedicine is enabling optimized, personalized treatments, with green nanotechnology advancing environmental safety and sustainability. Furthermore, nanomaterials are contributing to regenerative medicine and tissue engineering, facilitating precision tissue repair and stem cell modulation. Conclusion: Nanotechnology is revolutionizing the landscape of drug delivery by addressing the limitations of traditional systems and advancing medicine towards precision, adaptability, and sustainability. The ongoing progress in smart, multifunctional, and patient-specific nanomedicines, supported by clinical translation and regulatory approvals, underscores the vast therapeutic potential of this field.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2025-12-16</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijhse.com/index.php/files/article/view/12</dc:identifier>
	<dc:identifier>10.62896/ijhse.v1.i2.03</dc:identifier>
	<dc:source xml:lang="en">International Journal of Health Sciences and Engineering; IJHSE: Volume 1 , Issue 2, July-Dec, 2025; 22-34</dc:source>
	<dc:source>3049-3811</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijhse.com/index.php/files/article/view/12/9</dc:relation>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijhse.com:article/14</identifier>
				<datestamp>2025-12-16T10:40:06Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Technology Integration in Nursing Science</dc:title>
	<dc:creator xml:lang="en">Ali Mohammed Bashiri</dc:creator>
	<dc:creator xml:lang="en">Saleh Abdullah Alshehri</dc:creator>
	<dc:creator xml:lang="en">Mohammed Ali Mohammed Alshehri</dc:creator>
	<dc:creator xml:lang="en">Ali Abubakr Alshamrani</dc:creator>
	<dc:creator xml:lang="en">Faisal Abbad Alotaibi</dc:creator>
	<dc:subject xml:lang="en">Nursing science, Technology integration, Artificial intelligence, Telehealth, Simulation, Electronic health records, Patient outcomes.</dc:subject>
	<dc:description xml:lang="en">Background: Nursing science, traditionally grounded in compassionate and holistic care, is undergoing a transformative shift through technology integration. Advances in electronic health records (EHRs), artificial intelligence (AI), robotics, telehealth, and simulation-based education have redefined clinical practice, education, and research. This evolution addresses critical gaps in traditional nursing practice, such as fragmented communication, manual documentation errors, and delayed clinical decision-making. Methodology: This review critically examined literature, historical developments, and current applications of technology in nursing, synthesizing evidence across clinical, educational, and research domains. The analysis focused on technological tools, implementation challenges, and their impact on patient care, professional development, and system efficiency. Results: Findings indicate that technology enhances patient safety, improves workflow efficiency, supports predictive analytics, and strengthens nursing education through simulation and immersive learning. AI and wearable devices enable personalized and proactive care, while telehealth expands access in underserved populations. However, barriers such as high costs, digital literacy gaps, workflow disruptions, resistance to change, and cybersecurity concerns persist. Ethical implications—especially regarding AI and patient data—remain central to responsible integration. Conclusion: Technology integration has become indispensable in nursing science, enabling precision, efficiency, and global connectivity while preserving nursing’s foundational values of compassion and advocacy. Overcoming financial, infrastructural, and ethical challenges will require sustained leadership, inclusive training, and robust policy frameworks. Future directions point toward precision nursing, AI-driven care, robotics, and smart hospital ecosystems, ensuring equitable access and advancing nursing science worldwide.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2025-12-16</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijhse.com/index.php/files/article/view/14</dc:identifier>
	<dc:identifier>10.62896/ijhse.v1.i2.04</dc:identifier>
	<dc:source xml:lang="en">International Journal of Health Sciences and Engineering; IJHSE: Volume 1 , Issue 2, July-Dec, 2025; 35-46</dc:source>
	<dc:source>3049-3811</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijhse.com/index.php/files/article/view/14/10</dc:relation>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijhse.com:article/15</identifier>
				<datestamp>2025-12-16T10:40:06Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Community Engagement Strategies in Enhancing General Social Services</dc:title>
	<dc:creator xml:lang="en">Mofareh Dukhi Albaqami</dc:creator>
	<dc:creator xml:lang="en">Hussain Mohammed Alqahtani</dc:creator>
	<dc:creator xml:lang="en">Khalil Eid Alharbi</dc:creator>
	<dc:creator xml:lang="en">Alotaibi</dc:creator>
	<dc:creator xml:lang="en">Abdulrahman Muslim Almutairi</dc:creator>
	<dc:subject xml:lang="en">Community engagement, social services, empowerment, participatory models, equity, sustainability, co-creation.</dc:subject>
	<dc:description xml:lang="en">Background: Community engagement is increasingly recognized as a vital approach in strengthening general social services by ensuring inclusivity, equity, and sustainability. Methodology: This review synthesizes theoretical models, historical evolution, and practical frameworks of community engagement, examining strategies such as public dialogue, participatory planning, co-creation, educational outreach, digital engagement, and participatory research. Both needsbased and strengths-based approaches were considered to highlight their roles in service design and delivery. Results: Evidence indicates that effective engagement improves trust, social capital, cultural relevance, and accountability in service provision. Engagement levels ranging from community-oriented to community-owned models demonstrate varying impacts, with deeper community involvement fostering empowerment, resilience, and sustainable change. Success factors include tailoring approaches to context, building trust, empowering marginalized groups, and fostering collaborative partnerships. Conclusion: Community engagement is a transformative process in general social services, shifting the paradigm from top-down delivery to inclusive, communitydriven models. By prioritizing local voices and co-ownership, engagement strategies enhance service responsiveness, promote social justice, and create sustainable pathways for improved social outcomes.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2025-12-16</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijhse.com/index.php/files/article/view/15</dc:identifier>
	<dc:identifier>10.62896/ijhse.v1.i2.05</dc:identifier>
	<dc:source xml:lang="en">International Journal of Health Sciences and Engineering; IJHSE: Volume 1 , Issue 2, July-Dec, 2025; 47-57</dc:source>
	<dc:source>3049-3811</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijhse.com/index.php/files/article/view/15/11</dc:relation>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijhse.com:article/18</identifier>
				<datestamp>2025-12-16T10:40:05Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">AI-Driven Personalized Cognitive Behavioral Therapy: Future Potential and Risks</dc:title>
	<dc:creator xml:lang="en">Arwa Abdulaziz M Alghofaily</dc:creator>
	<dc:creator xml:lang="en">Meshari Jabr Aljuaid</dc:creator>
	<dc:subject xml:lang="en">Cognitive Behavioral Therapy, Artificial Intelligence, Personalized Therapy, Digital Mental Health, Chatbots, Machine Learning, Ethical Challenges, Patient Engagement.</dc:subject>
	<dc:description xml:lang="en">Background: Cognitive Behavioral Therapy (CBT) is a gold-standard intervention for depression, anxiety, and related disorders. With the growth of digital mental healthcare, Artificial Intelligence (AI) has emerged as a transformative force, enabling personalization, real-time monitoring, and scalability. AI-driven CBT tools, including chatbots, natural language processing, and machine learning models, are now capable of tailoring interventions dynamically, reducing dropout rates, and expanding access to underserved populations. Methodology: This review consolidates findings from randomized controlled trials, metaanalyses, implementation studies, and economic evaluations of AIenabled CBT platforms. It examines technological modalities such as conversational AI, predictive machine learning, and adaptive generative AI tools. Emphasis is placed on clinical efficacy, engagement metrics, safety considerations, ethical challenges, and scalability across diverse populations. Results: Evidence demonstrates that AI-driven CBT achieves moderate-to-high symptom reduction in depression and anxiety, with improved adherence compared to static digital interventions. Platforms like Woebot and Wysa show reduced dropout rates and higher therapeutic alliance through personalized interactions. Machine learning enhances risk stratification and symptom prediction, while economic models reveal cost-effectiveness in public health systems. Nonetheless, key risks persist, including data privacy concerns, algorithmic bias, reduced human connection, and clinical safety issues requiring rigorous oversight. Conclusion: AI-driven personalized CBT has strong potential to revolutionize mental healthcare by improving access, scalability, and treatment personalization while lowering costs. However, ethical safeguards, cultural sensitivity, and hybrid clinician-AI models are essential to balance automation with human empathy. Future development should focus on explainable AI, equity-driven design, and robust clinical validation to ensure safe and effective adoption.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2025-12-16</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijhse.com/index.php/files/article/view/18</dc:identifier>
	<dc:identifier>10.62896/ijhse.v1.i2.06</dc:identifier>
	<dc:source xml:lang="en">International Journal of Health Sciences and Engineering; IJHSE: Volume 1 , Issue 2, July-Dec, 2025; 58-66</dc:source>
	<dc:source>3049-3811</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijhse.com/index.php/files/article/view/18/12</dc:relation>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header status="deleted">
				<identifier>oai:ojs.ijhse.com:article/19</identifier>
				<datestamp>2026-01-16T11:36:14Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijhse.com:article/21</identifier>
				<datestamp>2026-01-16T11:45:13Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Immunological Memory in Viral Infections: Lessons from COVID-19</dc:title>
	<dc:creator xml:lang="en">Vivaswaan Pandey</dc:creator>
	<dc:subject xml:lang="en">Immunological Memory, Immune System, Cellular Memory, Vaccination, mRNA vaccin</dc:subject>
	<dc:description xml:lang="en">Immunological memory is basically the immune system’s way of not starting from scratch every time it sees a virus. Once the body has gone through that first encounter, the next one is usually quicker and more effective-though how well this works can depend a lot on the virus itself. B cells and T cells are the central players here, but over the past few years scientists have noticed that even some innate immune cells can be “trained” to respond a little better the second time. The strength and the durability of this memory, however, are uneven. Some viruses, like measles, give protection that pretty much lasts a lifetime. Others, such as the seasonal coronaviruses, don’t leave much of a lasting impression at all, which is why people can keep catching them. COVID-19 came along and forced researchers to study these differences in real time. Both infection and vaccination against SARS-CoV-2 create a layered form of immune memory-antibodies at first, but also memory B cells and T cells that stick around. The antibody levels fade within a few months, but the cellular memory seems to last longer and has been especially important in preventing serious disease. Vaccination, especially with the mRNA platforms, has turned out to be very effective in building this long-term memory. And when people have both infection and vaccination- so-called hybrid immunity- the protection is broader and more durable than either alone. That said, the story isn’t finished. People respond differently depending on age and health, the virus itself keeps mutating, and the current vaccines don’t really boost mucosal immunity in the respiratory tract. Understanding all of this in the context of COVID-19 doesn’t just help with today’s vaccine strategies- it also gives clues for how we might handle whatever virus shows up next.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2026-01-16</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijhse.com/index.php/files/article/view/21</dc:identifier>
	<dc:identifier>10.62896/ijhse.v2.i1.01</dc:identifier>
	<dc:source xml:lang="en">International Journal of Health Sciences and Engineering; IJHSE: Volume 2, Issue 1, Jan-June, 2026; 01-16</dc:source>
	<dc:source>3049-3811</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijhse.com/index.php/files/article/view/21/15</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2026 International Journal of Health Sciences and Engineering</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijhse.com:article/22</identifier>
				<datestamp>2026-01-16T11:53:00Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Transforming Drug Discovery and Wellness Through AI-Powered Scientific Prompt Generation: A White Paper on Swalife Biotech&#039;s Discovery Suite</dc:title>
	<dc:creator xml:lang="en">Pravin Badhe</dc:creator>
	<dc:subject xml:lang="en">Artificial intelligence; Drug discovery; Scientific prompt generation; Wellness innovation; Computational biology; Swalife Biotech; Discovery platforms</dc:subject>
	<dc:description xml:lang="en">The convergence of artificial intelligence (AI) and life sciences is redefining the landscape of drug discovery and preventive healthcare. AI-powered scientific prompt generation has emerged as a novel approach to accelerating research workflows, enhancing hypothesis development, and supporting data-driven decision-making. This white paper presents Swalife Biotech’s Discovery Suite, an integrated AI-driven platform designed to transform drug discovery and wellness innovation through intelligent prompt engineering tailored to scientific and biomedical applications. By leveraging domain-specific knowledge, machine learning models, and structured scientific reasoning, the Discovery Suite enables efficient target identification, lead optimization, and wellness solution development. The platform supports multidisciplinary research by bridging computational intelligence with biological insight, reducing development timelines, and improving translational relevance. This approach highlights the growing role of AI-assisted scientific creativity in advancing therapeutic discovery and personalized wellness strategies.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2026-01-16</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijhse.com/index.php/files/article/view/22</dc:identifier>
	<dc:identifier>10.62896/ijhse.v2.i1.03</dc:identifier>
	<dc:source xml:lang="en">International Journal of Health Sciences and Engineering; IJHSE: Volume 2, Issue 1, Jan-June, 2026; 22-27</dc:source>
	<dc:source>3049-3811</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijhse.com/index.php/files/article/view/22/16</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2026 International Journal of Health Sciences and Engineering</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijhse.com:article/23</identifier>
				<datestamp>2026-01-16T11:53:00Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Transforming Ocular Toxicity Assessment Through AI: A White Paper on the ICE Test Analysis Tool</dc:title>
	<dc:creator xml:lang="en">Pravin Badhe</dc:creator>
	<dc:subject xml:lang="en">Ocular toxicity; Artificial intelligence; ICE test; Eye irritation assessment; Alternative toxicity testing; Image analysis; Predictive modeling</dc:subject>
	<dc:description xml:lang="en">Ocular toxicity assessment is a critical component of safety evaluation for pharmaceuticals, chemicals, and consumer products. The Isolated Chicken Eye (ICE) test is a widely accepted alternative method for identifying severe eye irritants, offering ethical and scientific advantages over traditional in vivo testing. Recent advances in artificial intelligence (AI) have opened new opportunities to enhance the accuracy, consistency, and efficiency of ICE test analysis. This white paper explores the integration of AI-driven analytical frameworks into ocular toxicity assessment, focusing on automated data interpretation, image-based scoring, and predictive modeling. By reducing subjectivity and improving reproducibility, AI-supported ICE test analysis has the potential to strengthen decision-making, accelerate safety evaluations, and support regulatory acceptance. The convergence of AI and alternative toxicity testing represents a transformative step toward more reliable, ethical, and data-driven ocular safety assessment.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2026-01-16</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijhse.com/index.php/files/article/view/23</dc:identifier>
	<dc:identifier>10.62896/ijhse.v2.i1.02</dc:identifier>
	<dc:source xml:lang="en">International Journal of Health Sciences and Engineering; IJHSE: Volume 2, Issue 1, Jan-June, 2026; 17-21</dc:source>
	<dc:source>3049-3811</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijhse.com/index.php/files/article/view/23/17</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2026 International Journal of Health Sciences and Engineering</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijhse.com:article/27</identifier>
				<datestamp>2026-02-17T05:30:51Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">AI-Driven Ocular and Neurological Screening: A Comprehensive Review of the Swalife Eye Diagnostic Tool</dc:title>
	<dc:creator xml:lang="en">Pravin Badhe</dc:creator>
	<dc:creator xml:lang="en">Supriyo Acharya</dc:creator>
	<dc:subject xml:lang="en">AI ophthalmology, ocular disease detection, neurological screening, digital diagnostics, telemedicine, eye-movement analytics</dc:subject>
	<dc:description xml:lang="en">The convergence of artificial intelligence and ophthalmology has created unprecedented opportunities for early disease detection and neurological assessment through ocular biomarkers. This review examines the landscape of AI-based diagnostic systems with a particular focus on the Swalife Eye Diagnostic Tool, an integrated platform combining ocular disease detection with neurological indicator analysis. The tool addresses critical gaps in current screening methodologies by offering multi-disease capability, accessibility through standard image/video inputs, and automated clinical interpretation. We discuss the current state of AI in ocular diagnostics, the clinical rationale for integrated eye-brain assessment, the Swalife platform&#039;s architecture and functional capabilities, comparative advantages over existing systems, and clinical applications intelemedicine and population health. Strengths include rapid, scalable screening with standardized risk assessment and neurological metric evaluation; limitations include dependency on image quality and the need for comprehensive clinical validation. Future directions encompass expanded disease detection, integration with advanced imaging modalities, and real-time monitoring capabilities. The Swalife tool represents a significant advancement toward democratizing access to sophisticated ocular and neuro-oculomotor screening in diverse clinical and research settings.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2026-02-14</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijhse.com/index.php/files/article/view/27</dc:identifier>
	<dc:identifier>10.62896/ijhse.v2.i1.04</dc:identifier>
	<dc:source xml:lang="en">International Journal of Health Sciences and Engineering; IJHSE: Volume 2, Issue 1, Jan-June, 2026; 28-34</dc:source>
	<dc:source>3049-3811</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijhse.com/index.php/files/article/view/27/19</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2026 International Journal of Health Sciences and Engineering</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
	</ListRecords>
</OAI-PMH>
